Samarqand

This research aims to evaluate the safety and effectiveness of Reamberin solution for infusion, 1.5%, as a treatment for viral enteric infections in children aged 1 to 6 years. The study focuses on children of both sexes who have been diagnosed with viral intestinal infections and show clinical signs of intoxication. The goal is to assess the use of this drug in routine clinical practice for pathogenetic therapy. Participants receive either Reamberin at a daily dose of 10 mLkg combined with normal saline or glucose solutions, or standard infusion therapy such as normal saline, Ringers solution, or glucose solutions alone. The study is observational and open, with treatment decisions made by physicians, and it monitors the patients during the course of infusion therapy. Children enrolled in the study will be closely monitored for various health outcomes including the duration of infusion therapy, symptoms related to gastrointestinal tract damage, intoxication, fever, and hospital stay length. Assessments will be made at 24 and 48 hours after treatment begins and on day 10 to evaluate therapy continuation, symptom dynamics, electrolyte balance, dehydration severity, and blood parameters. The total study participation spans these key timepoints to track the therapys impact and safety.

Researchers are studying the connection between coronary heart disease, specifically unstable angina pectoris, and anxiety-depressive syndrome. The trial includes 202 patients, with 160 having unstable angina and 42 having stable angina as a control group. The study aims to explore how these heart conditions and mental health issues might influence each other, using established diagnostic criteria and scales to assess anxiety, depression, and cognitive function. Participants undergo blood draws in the morning after fasting for 8-12 hours to measure levels of cytokines TNF-b1, IL-1b2, IL-4, IL-10 using enzyme-linked immunosorbent assay ELISA and uric acid levels. Patients with unstable angina receive conventional therapy including nitrates, beta-blockers, ACE inhibitors or sartans, antiplatelet agents, and statins. Those with elevated uric acid are treated with Febuxostat, and patients with anxiety-depressive syndrome receive Divase syndrome, a neurotropic and antioxidant medication. Throughout the study, participants complete anxiety and depression assessments using the Hospital Anxiety and Depression Scale and the Spielberger-Khanin Anxiety Scale. Researchers track cytokine and uric acid levels from 2019 to 2027 to understand the immune and biochemical profiles linked to these conditions. The study also monitors cognitive functions and allows patients to withdraw at any time, with ongoing evaluation to support patient safety and well-being.